Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

New York State Common Retirement Fund increased its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Rating) by 166.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 51,790 shares of the company's stock after buying an additional 32,322 shares during the quarter. New York State Common Retirement Fund owned 0.07% of Day One Biopharmaceuticals worth $1,037,000 as of its most recent filing with the Securities & Exchange Commission. Pneumatic Brake

Other hedge funds also recently made changes to their positions in the company. Prudential Financial Inc. bought a new stake in Day One Biopharmaceuticals in the third quarter valued at $767,000. Barclays PLC boosted its holdings in Day One Biopharmaceuticals by 7,615.8% in the third quarter. Barclays PLC now owns 90,429 shares of the company's stock valued at $1,812,000 after acquiring an additional 89,257 shares in the last quarter. ExodusPoint Capital Management LP bought a new stake in Day One Biopharmaceuticals in the second quarter valued at $412,000. Goldman Sachs Group Inc. boosted its holdings in Day One Biopharmaceuticals by 5,969.9% in the second quarter. Goldman Sachs Group Inc. now owns 1,894,537 shares of the company's stock valued at $33,912,000 after acquiring an additional 1,863,325 shares in the last quarter. Finally, Macquarie Group Ltd. bought a new stake in Day One Biopharmaceuticals in the second quarter valued at $1,969,000. 86.08% of the stock is owned by hedge funds and other institutional investors. Insider Transactions at Day One Biopharmaceuticals

In other news, CEO Jeremy Bender sold 3,022 shares of Day One Biopharmaceuticals stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $19.57, for a total value of $59,140.54. Following the completion of the transaction, the chief executive officer now owns 1,186,776 shares of the company's stock, valued at approximately $23,225,206.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Day One Biopharmaceuticals news, CFO Charles N. York II sold 10,000 shares of the business's stock in a transaction dated Tuesday, December 20th. The stock was sold at an average price of $20.07, for a total value of $200,700.00. Following the completion of the transaction, the chief financial officer now owns 276,497 shares of the company's stock, valued at approximately $5,549,294.79. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Jeremy Bender sold 3,022 shares of the business's stock in a transaction dated Thursday, February 16th. The stock was sold at an average price of $19.57, for a total value of $59,140.54. Following the completion of the transaction, the chief executive officer now directly owns 1,186,776 shares of the company's stock, valued at approximately $23,225,206.32. The disclosure for this sale can be found here. Insiders sold a total of 113,984 shares of company stock valued at $2,412,755 in the last quarter. 8.70% of the stock is owned by insiders. Day One Biopharmaceuticals Stock Up 2.6 %

DAWN opened at $20.05 on Tuesday. The stock has a 50-day moving average price of $21.16 and a 200-day moving average price of $21.42. Day One Biopharmaceuticals, Inc. has a 1 year low of $5.44 and a 1 year high of $28.35. Analyst Ratings Changes

DAWN has been the topic of several recent analyst reports. Needham & Company LLC initiated coverage on shares of Day One Biopharmaceuticals in a report on Wednesday, December 14th. They issued a "buy" rating and a $40.00 price target on the stock. HC Wainwright boosted their target price on shares of Day One Biopharmaceuticals from $35.00 to $45.00 and gave the company a "buy" rating in a report on Monday, January 9th. Capital One Financial assumed coverage on shares of Day One Biopharmaceuticals in a report on Wednesday, February 8th. They set an "overweight" rating and a $40.00 target price on the stock. The Goldman Sachs Group boosted their target price on shares of Day One Biopharmaceuticals from $45.00 to $62.00 and gave the company a "buy" rating in a report on Monday, January 9th. Finally, Oppenheimer assumed coverage on shares of Day One Biopharmaceuticals in a report on Thursday, February 2nd. They set a "market perform" rating on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Day One Biopharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $43.00.Day One Biopharmaceuticals Profile (Get Rating)

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma.Further ReadingGet a free copy of the StockNews.com research report on Day One Biopharmaceuticals (DAWN)Is Alibaba the Jet fuel Launching China into New Frontiers?Applied Materials Is In The Semiconductor Sweet Spot Can Coinbase Shake Off Regulatory Risk After Kraken's Shakedown?Tripadvisor Stock Gap and Crap. Here’s Why. Could Copper be the Shiny Object That Lifts Barrick Gold?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Day One Biopharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Day One Biopharmaceuticals wasn't on the list.

While Day One Biopharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

326 E 8th St #105, Sioux Falls, SD 57103 contact@marketbeat.com (844) 978-6257

© American Consumer News, LLC dba MarketBeat® 2010-2023. All rights reserved.

Magnabend Folding Machine © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.